Fluvoxamine Does Not Shorten Duration of COVID-19 Symptoms

Follow Drugslib on

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

TUESDAY, Nov. 28, 2023 -- Fluvoxamine does not reduce duration of COVID-19 symptoms in patients with mild or moderate COVID-19, according to a study published online Nov. 17 in the Journal of the American Medical Association.

Thomas G. Stewart, Ph.D., from the University of Virginia in Charlottesville, and colleagues from the Accelerating COVID-19 Therapeutic Interventions and Vaccines-6 Study Group assessed the effectiveness of fluvoxamine versus placebo for treating mild to moderate COVID-19. The analysis included 1,208 participants randomly assigned to receive fluvoxamine (50 mg twice daily on day 1 followed by 100 mg twice daily for 12 additional days; 601 patients) or placebo (607 patients).

The researchers found no differences in time to sustained recovery between the two groups (adjusted hazard ratio, 0.99; 95 percent credible interval, 0.89 to 1.09; P for efficacy = 0.40). Similarly, in both groups, unadjusted median time to sustained recovery was 10 days. No deaths were reported, but 35 participants reported health care use events (defined as death, hospitalization, or emergency department/urgent care visit), including 14 in the fluvoxamine group and 21 in the placebo group (hazard ratio, 0.69; 95 percent credible interval, 0.27 to 1.21; P for efficacy = 0.86). Seven serious adverse events occurred in six participants (two with fluvoxamine and four with placebo).

"Although one-third fewer health care use events occurred in the fluvoxamine intervention group, the difference did not meet prespecified decision thresholds for concluding a treatment effect," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Editor's Note

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2023-11-29 00:32

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords